BBIO 241220 12.50P (BBIO241220P12500) Stock Options, News & Quotes

$BridgeBio Pharma (BBIO.US)$
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
BridgeBio Pharma announced FDA approval of Attruby™ (acoramidis) for treating adults with ATTR-CM to reduce cardiovascular death and hospitalization.
The approval is based on the ATTRibute-CM Phase 3 study results, showing a 42% reduction in composite all-cause mortality and recurrent cardiovasc...

Trytosaveabit

Nov 22 18:42

T 1 News Halt!

$BridgeBio Pharma (BBIO.US)$ Reuters
28 mins ago
Attruby™ (Acoramidis), a Near Complete Ttr Stabilizer (≥90%), Approved by FDA to Reduce Cardiovascular Death and Cardiovascular-Related Hospitalization in Attr-Cm Patients
BridgeBio Pharma Inc - to Receive $500 Million Payment Under Royalty Agreement
BridgeBio Pharma Inc - Grants Bayer Rights to Commercialize Acoramidis in Europe

Stock_Drift

Feb 2 04:12

$AstraZeneca (AZN.US)$ $BridgeBio Pharma (BBIO.US)$ $ASTRAZENECA PLC (AZNCF.US)$
📊⚡️📊

AstraZeneca's Results From Japan Phase 3 Trial Of Acoramidis For Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) Is Consistent With BridgeBio Pharma's ATTRibute-CM Phase 3 Trial, Including Survival, Cardiac-Related Hospitalizations

Movers and Shakers

Jan 31 07:07

Columns Today's Morning Movers and Top Ratings: GOOGL, AMD, TSLA, SBUX and More

Morning Movers
Gapping up
$Starbucks (SBUX.US)$ stock rose 3.7% after the coffee chain cut its annual sales forecast, warning of softer demand in January and a slow recovery in China. However, even more weakness had been expected following disappointing store traffic in November and December.
$Novo-Nordisk A/S (NVO.US)$ stock rose 0.5% after the Danish drugmaker forecast another year of double-digit growth due to the populari...